Larimar Therapeutics Added to NASDAQ Biotechnology Index
15 déc. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
08 déc. 2020 07h30 HE
|
Larimar Therapeutics, Inc.
- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo-controlled single...
Larimar Therapeutics to Participate in Upcoming Investor Conferences
13 nov. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
10 nov. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia on track for topline data in 1H 2021 Received orphan drug designation for CTI-1601 from the European Commission Cash, cash...
Larimar Therapeutics Announces Formation of Scientific Advisory Board
13 oct. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
21 sept. 2020 09h58 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
10 sept. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
11 août 2020 07h00 HE
|
Larimar Therapeutics, Inc.
Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar TherapeuticsPhase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after...
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
04 août 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
28 juil. 2020 08h00 HE
|
Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...